carrito Compra

(0 Productos)

Gastos de envío GRATIS

Solo para España


PLATELET GLYCOPROTEIN IIB - IIIa INHIBITORS IN CARDIOVASCULAR DISEASE

PLATELET GLYCOPROTEIN IIB - IIIa INHIBITORS IN CARDIOVASCULAR DISEASE-9781588291851
  1. Autor:

    Lincoff

  2. Isbn:

    9781588291851

  3. Páginas:

    440

  4. Año:

    2003

  5. Edición:

    2

  6. Idioma:

    Ingles

  7. Disponibilidad:

    De 2 a 3 Semanas

Precio s/iva:

127.20 €

120,84  €
Volver

DESCRIPTION:
This substantially revised second edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes or with fibrinolytic therapy during acute myocardial infarctions, and updated and expanded information on the latest trials of GP IIb/IIIa inhibition during percutaneous coronary intervention. Additional improvements include a new chapter on outcomes with chronic oral GP IIb/IIIa blockade following acute coronary syndromes, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. Platelet Glycoprotein IIb/IIIa inhibitors in Cardiovascular Disease, Second Edition offers today""s physicians, cardiologists, emergency room doctors, and basic scientists the most complete and authoritative review of the state-of-the-art in glycoprotein Iib/IIIa receptor inhibitor use.

CONTENTS:
PART I BASIC PRINCIPLES
1 Thrombosis in Acute Coronary Syndromes and Coronary Interventions
2 Platelet Adhesion
3 Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis
4 Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Abciximab, Tirofiban, and Eptifibatide

PART II GLYCOPROTEIN IIB/IIIA BLOCKADE DURING CORONARY INTERVENTION
5 Abciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT Trials
6 Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials
7 Tirofiban in Interventional Cardiology: The RESTORE and TARGET Trials
8 Overview of the Glycoprotein IIb/IIIa Interventional Trials

PART III GLYCOPROTEIN IIB/IIIA BLOCKADE FOR ACUTE ISCHEMIC SYNDROMES
9 The Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE Study
10 Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV
11 Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy
12 Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary Interventions
13 Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to Fibrinolysis

PART IV PRACTICAL ISSUES AND FUTURE APPLICATIONS
14 Economics of Glycoprotein IIb/IIIa Inhibition
15 Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents
16 Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors
17 Oral Agents
18 Platelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the Platelet
19 Cerebrovascular Interventions
20 Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors
21 Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future



Libreria Médica Berri 2024 ®